Drug Profile
Research programme: factor IIa/Xa inhibitor - Sanofi-Aventis
Alternative Names: SSR 128429Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 01 Mar 2005 This compound is still in active development
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 15 Jul 2003 Preclinical trials in Thrombosis in Europe (unspecified route)